1. Home
  2. AOD vs GERN Comparison

AOD vs GERN Comparison

Compare AOD & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo abrdn Total Dynamic Dividend Fund of Beneficial Interest

AOD

abrdn Total Dynamic Dividend Fund of Beneficial Interest

HOLD

Current Price

$10.51

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.41

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AOD
GERN
Founded
N/A
1990
Country
United States
United States
Employees
N/A
229
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
2006
N/A

Fundamental Metrics

Financial Performance
Metric
AOD
GERN
Price
$10.51
$1.41
Analyst Decision
Hold
Analyst Count
0
3
Target Price
N/A
$2.17
AVG Volume (30 Days)
409.3K
15.7M
Earning Date
01-01-0001
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
N/A
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.38
$1.04
52 Week High
$10.77
$2.01

Technical Indicators

Market Signals
Indicator
AOD
GERN
Relative Strength Index (RSI) 64.16 40.28
Support Level $9.82 $1.24
Resistance Level $10.77 $1.49
Average True Range (ATR) 0.12 0.09
MACD 0.02 -0.01
Stochastic Oscillator 88.06 15.07

Price Performance

Historical Comparison
AOD
GERN

About AOD abrdn Total Dynamic Dividend Fund of Beneficial Interest

Aberdeen Total Dynamic Dividend Fund is a diversified, closed-end management investment company. Its investment objective is to seek high current dividend income. The company also focuses on the long-term growth of capital as a secondary investment objective. The fund invests in foreign securities, including direct investments in securities of foreign issuers and investments in depositary receipts that represent indirect interests in securities of foreign issuers. Its portfolio consists of securities from Information Technology, Financial, Healthcare, and Industrials among other sectors.

About GERN Geron Corporation

Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.

Share on Social Networks: